8 active not recruiting. 8 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 8 |
| Phase 1 | 4 | Active not recruiting 4 |
Follow Hydroxychloroquine: new trials by email Literature Review of Hydroxychloroquine trials Research Report on Hydroxychloroquine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer Hydroxychloroquine, Irinotecan, Leucovorin - Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | University Health Network, Toronto | 155 | 2023-08-09 | 2026-06-22 |
| Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis Hydroxychloroquine, Mesalamine - Ulcerative Colitis (Disorder) | Phase 1 / Phase 2 | Active not recruiting | Icahn School of Medicine at Mount Sinai | 3 | 2022-06-10 | 2025-02-11 |
| Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer HCQ, Avelumab, Palbociclib - Breast Cancer | Phase 2 | Active not recruiting | Abramson Cancer Center at Penn Medicine | 96 | 2021-06-01 | 2026-10-16 |
| A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma Nivolumab, Hydroxychloroquine, Ipilimumab - Melanoma | Phase 1 / Phase 2 | Active not recruiting | Ravi Amaravadi, MD | 41 | 2020-10-21 | 2026-09-21 |
| A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration Dabrafenib, Trametinib, Hydroxychloroquine - Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration | Phase 1 / Phase 2 | Active not recruiting | Pediatric Brain Tumor Consortium | 57 | 2020-01-17 | 2026-09-11 |
| Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma Docetaxel, Gemcitabine, Hydroxychloroquine - Recurrent Osteosarcoma, Refractory Osteosarcoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 31 | 2019-01-28 | 2026-05-14 |
| CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer Hydroxychloroquine, Everolimus - Breast Cancer Stage IIB | Phase 2 | Active not recruiting | Abramson Cancer Center at Penn Medicine | 53 | 2017-01-23 | 2026-06-29 |
| Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations Erlotinib, Hydroxychloroquine - Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Massachusetts General Hospital | 76 | 2009-10-01 | 2025-10-15 |
Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Colitis, Ulcerative (1) · Colorectal Neoplasms (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Glioma (1) · Inflammatory Bowel Diseases (1) · Melanoma (1) · Neoplasm, Residual (1) · Osteosarcoma (1)
Abramson Cancer Center at Penn Medicine (2) · Icahn School of Medicine at Mount Sinai (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Pediatric Brain Tumor Consortium (1) · Ravi Amaravadi, MD (1) · University Health Network, Toronto (1)
United States (7) · Canada (1)
Angela DeMichele, MD (2) · Eric Chen, MD (1) · John A Livingston (1) · Judy H Cho, MD (1) · Lecia Sequist, MD (1) · Lindsey Hoffman, DO (1) · Ravi Amaravadi, MD (1) · Subra Kugathasan, MD (1)
UM1CA081457 (1)